Success Metrics

Clinical Success Rate
86.4%

Based on 19 completed trials

Completion Rate
86%(19/22)
Active Trials
6(20%)
Results Posted
111%(21 trials)
Terminated
3(10%)

Phase Distribution

Ph phase_3
2
7%
Ph phase_1
12
40%
Ph phase_2
15
50%
Ph early_phase_1
1
3%

Phase Distribution

13

Early Stage

15

Mid Stage

2

Late Stage

Phase Distribution30 total trials
Early Phase 1First-in-human
1(3.3%)
Phase 1Safety & dosage
12(40.0%)
Phase 2Efficacy & side effects
15(50.0%)
Phase 3Large-scale testing
2(6.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

82.6%

19 of 23 finished

Non-Completion Rate

17.4%

4 ended early

Currently Active

6

trials recruiting

Total Trials

30

all time

Status Distribution
Active(6)
Completed(19)
Terminated(4)
Other(1)

Detailed Status

Completed19
Active, not recruiting5
Terminated3
Recruiting1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
30
Active
6
Success Rate
86.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (3.3%)
Phase 112 (40.0%)
Phase 215 (50.0%)
Phase 32 (6.7%)

Trials by Status

recruiting13%
active_not_recruiting517%
withdrawn13%
terminated310%
unknown13%
completed1963%

Recent Activity

6 active trials
Showing 5 of 30
active_not_recruitingphase_1

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

NCT04847453
terminatedphase_2

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

NCT03506373
active_not_recruitingphase_2

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

NCT02339922
recruitingphase_2

Trial of Ixazomib for Kaposi Sarcoma

NCT04305691
completedphase_2

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

NCT02389517
View all 30 trials

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT04847453Phase 1

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Active Not Recruiting
NCT03506373Phase 2

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Terminated
NCT02339922Phase 2

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Active Not Recruiting
NCT04305691Phase 2

Trial of Ixazomib for Kaposi Sarcoma

Recruiting
NCT02389517Phase 2

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Completed
NCT03587662Phase 2

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Active Not Recruiting
NCT02619682Phase 2

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed
NCT02420847Phase 1

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Active Not Recruiting
NCT01415882Phase 2

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Completed
NCT01864018Phase 1

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Completed
NCT03770260Phase 1

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Completed
NCT03012880Phase 2

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed
NCT03941860Phase 3

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Completed
NCT04047797Phase 2

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Terminated
NCT03457142Phase 2

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Terminated
NCT02921893Early Phase 1

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Completed
NCT01718743Phase 2

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed
NCT02181413Phase 3

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Completed
NCT03399539Phase 1

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Completed
NCT02633059Phase 1

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
30